If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-15. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In 2001, the World Health Organization reported that data from Kosovo was inconclusive and called for further studies. That same year, governments of several European countries, particularly Italy, reported an increase in illnesses and developments of cancers among veterans that served in Balkan peacekeeping missions. A 2003 study by the United Nations Environment Programme (UNEP) in Bosnia and Herzegovina stated that low levels of contaminant were found in drinking water and air particulate at DU penetrator impact points. The levels were stated as not a cause for alarm. Yet, Pekka Haavisto, chairman of the UNEP DU projects stated, "The findings of this study stress again the importance of appropriate clean-up and civil protection measures in a post-conflict situation." A team of Italian scientists from the University of Siena reported in 2005 that, although DU was "clearly" added to the soil in the study area, "the phenomenon was very limited spatially and the total uranium concentrations fell within the natural range of the element in soils.
Symptoms include feverishness, a general sense of malaise, and pain or swelling around the genitals or in the skin behind them. The infection progresses quickly and urgent medical attention is recommended. Empagliflozin can increase the risk of low blood sugar when it is used together with a sulfonylurea or insulin. When used by itself or in addition to metformin it does not appear to increase the risk of hypoglycemia.
In 2023, Cambrex acquired the Waltham-headquartered chemical process development services provider, Snapdragon Chemistry. In 2024, Cambrex expanded Q1 Scientific with new state-of-the-art, temperature-controlled and monitored, stability storage facility in Durham, North Carolina. In 2025, Cambrex sold its large-scale drug product business unit to Noramco, including its two sites in Whippany, NJ and Mirabel, Quebec.
Clytia hemisphaerica reproduces sexually. Ovulated eggs are fertilized externally and take approximately 24 hours to develop into planula. The ciliated planula will swim freely until the proper external cues, for instance, experimental treatment with CsCl, trigger the metamorphic process. The planula can undergo its metamorphosis into a polyp as soon as three days after fertilization. Once the proper external cue is received, the planula stops swimming and attaches itself to a substrate via its aboral or aboral-lateral pole (what was previously the front end of the swimming planula). After attaching itself to a substrate, the planula contracts along its oral–aboral axis and so forms a flattened holdfast to anchor itself to the substrate.
Trammell, SAJ; Schmidt, MS; Weidemann, BJ; Redpath, P; Jaksch, F; Dellinger, RW; Li, Z; Abel, ED; Migaud, ME; Brenner, C (10 October 2016). "Nicotinamide riboside is uniquely and orally bioavailable in mice and humans". Nature Communications. 7 (1) 12948. Bibcode:2016NatCo...712948T. doi:10.1038/ncomms12948. PMC 5062546. PMID 27721479. Trammell, SAJ; Weidemann, BJ; Chadda, A; Yorek, MS; Holmes, A; Coppey, LJ; Obrosov, A; Kardon, RH; Yorek, MA; Brenner, C (2016). "Nicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice". Scientific Reports. 6 26933. Bibcode:2016NatSR...626933T. doi:10.1038/srep26933. PMC 4882590. PMID 27230286. Wu, B-K; Brenner, C (2014). "Suppression of TET1-Dependent DNA Demethylation Is Essential for KRAS-Mediated Transformation". Cell Reports. 9 (5): 1827–1840. doi:10.1016/j.celrep.2014.10.063. PMC 4268240. PMID 25466250. Fagan, RL; Cryderman, DE; Kopelovich, L; Wallrath, LL; Brenner, C (2013). "Laccaic Acid A Is a Direct, DNA-competitive Inhibitor of DNA Methyltransferase 1". J. Biol. Chem. 288 (33): 23858–23867. doi:10.1074/jbc.M113.480517. PMC 3745332. PMID 23839987. Brenner, C (2013). "Changes in Chemistry and Biochemistry Education: Creative Responses to MCAT Revisions in the Age of the Genome". Biochemistry and Molecular Biology Education. 41 (1): 1–4. doi:10.1002/bmb.20653. PMID 23281187. S2CID 4659938. Brenner, C (2013). "Rethinking Premedical and Health Professional Curricula in Light of MCAT 2015" (PDF). J. Chem. Educ. 90 (7): 807–812. Bibcode:2013JChEd..90..807B. doi:10.1021/ed4002738. S2CID 98274150.
Sources: en.wikipedia.org
== Protein purification == The importance of the Hofmeister series to early protein work should not be underestimated, since it provided the chief tool for purifying proteins (sulfate precipitation) over the next ~50 years, one that is still in use today. Hofmeister himself may have been the first to crystallize a protein, hen egg-white albumin. Repeated crystallization was a favourite purification technique in the early days of protein science, and was essential for its development.
IUPAC pointed out that the Berkeley laboratory had already been recognized several times, in the naming of berkelium, californium, and americium, and that the acceptance of the names rutherfordium and seaborgium for elements 104 and 106 should be offset by recognizing JINR's contributions to the discovery of elements 104, 105, and 106. Even after 1997, LBL still sometimes used the name hahnium for element 105 in their own material, doing so as recently as 2014. However, the problem was resolved in the literature as Jens Volker Kratz, editor of Radiochimica Acta, refused to accept papers not using the 1997 IUPAC nomenclature.
Pyruvate formate-lyase activating enzyme (PFL-AE) catalyzes the activation of PFL, a central enzyme in anaerobic glucose metabolism in microbes. Benzylsuccinate synthase (BSS) is a central enzyme in anaerobic toluene catabolism.
==== Auxiliary channel ==== The DisplayPort AUX channel is a half-duplex data channel used for miscellaneous additional data beyond video and audio, such as EDID (I2C) or CEC commands. This bidirectional data channel is required, since the video lane signals are unidirectional (simplex) from source to display. AUX signals are transmitted across a dedicated set of twisted-pair wires. DisplayPort 1.0 specified Manchester encoding with a 2 MBd signal rate (1 Mbit/s data rate). Version 1.2 of the DisplayPort standard introduced a second transmission mode called FAUX (Fast AUX), which operated at 720 Mbit/s with 8b/10b encoding (576 Mbit/s data rate), but it was deprecated in version 1.3.
=== Mechanical ventilation === Isolated mechanical forces may not adequately explain ventilator induced lung injury (VILI). The damage is affected by the interaction of these forces and the pre-existing state of the lung tissues, and dynamic changes in alveolar structure may be involved. Factors such as plateau pressure and positive end-expiratory pressure (PEEP) alone do not adequately predict injury. Cyclic deformation of lung tissue may play a large part in the cause of VILI, and contributory factors probably include tidal volume, positive end-expiratory pressure and respiratory rate. There is no protocol guaranteed to avoid all risk in all applications.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.